Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.44 |
| ▸ | NPY4R | P50391 | 10/20 | 0.43 |
| ▸ | NPY1R | P25929 | 8/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.43 |
| ▸ | NPY2R | P49146 | 4/20 | 0.43 |
| ▸ | CTSD | P07339 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24178182 | 1.00 | BACE1 (0.44) | BACE1NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL583830 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL13933715 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL4669504 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL11021602 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24178267 | 0.91 | SIRT5 (0.38) | BACE1NPY4RNPY1RNPY5RNPY2R | |
| Leupeptin SCHEMBL11596919 | 0.91 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3308386 | 0.91 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30643187 | 0.91 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16316642 | 0.87 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | YALE UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220002354-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN PROTEASE INHIBITORS AND ANALOGS THEREOF | YALE UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | LPXN, LAP3, PEPD | BACE1 1992/4885NPY4R 2718/4885NPY1R 2805/4885 |
| US-20220002354-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN PROTEASE INHIBITORS AND ANALOGS THEREOF | LPXN, LAP3, PEPD | BACE1 1992/4885NPY4R 2718/4885NPY1R 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.